Tirzepatide once weekly for treatment of obesity in patients with type 2 diabetes
The Lancet
2023
Study summary
SURMOUNT-2 examined tirzepatide for obesity in adults with type 2 diabetes.
Peptides studied
Goals studied
Stack studied
Advanced Metabolic Stack
Key findings
Substantial and clinically meaningful body-weight reduction was observed.
Study details
Study type
randomized clinical trial
Journal
The Lancet
DOI / PubMed
10.1016/S0140-6736(23)01200-X
Year
2023
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.